Antonina Dolgorukova

ORCID: 0000-0003-4189-7910
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Migraine and Headache Studies
  • Trigeminal Neuralgia and Treatments
  • Receptor Mechanisms and Signaling
  • Neurotransmitter Receptor Influence on Behavior
  • Electrolyte and hormonal disorders
  • Erythrocyte Function and Pathophysiology
  • Sympathectomy and Hyperhidrosis Treatments
  • Ion channel regulation and function
  • Pharmacogenetics and Drug Metabolism
  • Neuroendocrine regulation and behavior
  • Pain Mechanisms and Treatments
  • Ion Transport and Channel Regulation
  • Computational Drug Discovery Methods
  • COVID-19 Clinical Research Studies
  • Birth, Development, and Health
  • Neuroscience of respiration and sleep
  • Drug Transport and Resistance Mechanisms
  • Axon Guidance and Neuronal Signaling
  • Pharmaceutical studies and practices
  • Neural dynamics and brain function
  • COVID-19 and healthcare impacts
  • Cancer therapeutics and mechanisms
  • Vestibular and auditory disorders
  • Trace Elements in Health
  • Pharmacological Effects and Assays

First Pavlov State Medical University of St. Petersburg
2016-2023

R-Pharm (Russia)
2022-2023

Trace amine-associated receptor 1 (TAAR1) has emerged as a promising target for addiction treatments because it affects dopamine transmission in the mesolimbic pathway. TAAR1 is involved effects of addictive drugs, such amphetamines, cocaine and ethanol, but impact on nicotine, psychoactive drug responsible development maintenance tobacco smoking, not yet been studied. This study was performed to investigate possible modulatory action nicotine locomotor behaviours rats mice. Pretreatment...

10.3389/fphar.2018.00329 article EN cc-by Frontiers in Pharmacology 2018-04-06

The aim of the article is to study pharmacokinetic characteristics intravenous olokizumab in patients with moderate COVID-19 relieve a hyperinflammation syndrome. Materials and methods. was conducted as part phase III clinical (RESET, NCT05187793) on efficacy safety new regimen (intravenous, at doses 128 mg or 256 mg) patients. Plasma concentrations were determined by enzyme immunoassay. population analysis performed using previously developed model based linear two compartment. Results....

10.19163/2307-9266-2022-10-5-460-471 article EN cc-by Pharmacy & Pharmacology 2022-12-15

Журнал для непрерывного медицинского образования врачей Олокизумаб снижает риски летального исхода у госпитализированных пациентов с COVID-19 среднетяжелого и тяжелого течения РЕДАКЦИОННАЯ СТАТЬЯ1 Государственное бюджетное учреждение здравоохранения города Москвы «Городская клиническая больница имени Ф.И.Иноземцева Департамента Москвы»,

10.33029/2305-3496-2022-11-4-8-18 article RU Infectious diseases News Opinions Training 2022-01-01

Nirmatrelvir is an antiviral drug that, in combination with ritonavir, effective agent for the etiotropic therapy of patients mild to moderate COVID-19. The aim study was evaluate bioequivalence generic nirmatrelvir Аrpaxel ritonavir and original Paxlovid, which a nirmatrelvir/ritonavir, single dose administration healthy volunteers. Materials methods. This research open-label, randomized, two-period crossover study. It included 2 periods, each volunteers received either test (nirmatrelvir...

10.19163/2307-9266-2023-11-1-62-71 article EN cc-by Pharmacy & Pharmacology 2023-04-28

Transcranial Doppler ultrasonography is used to study intracranial blood flow changes associated with migraine in humans, but whether this method helpful preclinical settings yet unknown. To identify rat specific trigeminovascular activation-a key process pathophysiology-we measured indices the middle cerebral artery and basilar before, during, after dural or somatosensory electrical stimulation. Hemodynamic stimulation were tested further separate experiments. After baseline recordings,...

10.1139/cjpp-2021-0626 article EN Canadian Journal of Physiology and Pharmacology 2022-04-12

Abstract The low reliability of the preclinical study’s findings is critical concern. possible sources include poor experimental design and a lack measures to reduce risk bias. In this study, we focused on anti-migraine drug discovery particular animal model with aim contribute elimination these in future research. We performed systematic search controlled studies testing established migraine treatments trigeminovascular nociception (EMTVN) meta-analysis for main outcomes estimate overall...

10.1101/2022.07.05.498780 preprint EN cc-by-nd bioRxiv (Cold Spring Harbor Laboratory) 2022-07-05
Coming Soon ...